Biotech · Public company · Concord, MA, US

Aldeyra Therapeutics, Inc.

Ticker ALDX · SEC CIK 0001341235

Track this companyFree. Adds Aldeyra Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials251 recruiting or active

Pipeline programs38From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline38

ADX-102 1% Topical Dermal Cream (reproxalap)Phase 3 · Sjogren-Larsson SyndromeClinicalTrials.gov · fetched Nov 12, 2026
ADX-102 Ophthalmic Solution (0.5%)Phase 3 · Non-infectious Anterior UveitisClinicalTrials.gov · fetched Nov 12, 2026
ADX-2191 (intravitreal methotrexate 0.8%)Phase 3 · Proliferative VitreoretinopathyClinicalTrials.gov · fetched Nov 12, 2026
ICM ADX-2191 injectionPhase 3 · Primary Vitreoretinal LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Monthly ADX-2191 injectionPhase 3 · Primary Vitreoretinal LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Reproxalap Ophthalmic Solution (0.25%)Phase 3 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
Reproxalap Ophthalmic Solution (0.25%)Phase 3 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
Reproxalap Ophthalmic Solution (0.25%)Phase 3 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Reproxalap Ophthalmic Solution (0.25%) QIDPhase 3 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
Reproxalap Ophthalmic Solution (0.25%) QID to BIDPhase 3 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
Reproxalap Ophthalmic Solution (0.5%)Phase 3 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
Standard surgical care procedurePhase 3 · Proliferative VitreoretinopathyClinicalTrials.gov · fetched Nov 12, 2026
Vehicle of ADX-102 Ophthalmic SolutionPhase 3 · Non-infectious Anterior UveitisClinicalTrials.gov · fetched Nov 12, 2026
Vehicle of ADX-102 Topical Dermal CreamPhase 3 · Sjogren-Larsson SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Vehicle Ophthalmic SolutionPhase 3 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Vehicle Ophthalmic SolutionPhase 3 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
Vehicle Ophthalmic SolutionPhase 3 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
Vehicle Ophthalmic Solution QIDPhase 3 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
Vehicle Ophthalmic Solution QID to BIDPhase 3 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
Vehicle Opthalmic SolutionPhase 3 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
ADX-102 Ophthalmic Lipid Solution (0.5%)Phase 2 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
ADX-102 Ophthalmic Solution (0.1%)Phase 2 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
ADX-102 Ophthalmic Solution (0.5%)Phase 2 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
ADX-2191Phase 2 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
ADX-629Phase 2 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
ADX-629Phase 2 · Chronic CoughClinicalTrials.gov · fetched Nov 12, 2026
ADX-629Phase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
ADX-629Phase 2 · Nephrotic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
ADX-629Phase 2 · Ethanol IntoxicationClinicalTrials.gov · fetched Nov 12, 2026
ADX-629Phase 2 · Alcohol HepatitisClinicalTrials.gov · fetched Nov 12, 2026
ADX-629 (Open-label)Phase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
NS2Phase 2 · Non-infectious Anterior UveitisClinicalTrials.gov · fetched Nov 12, 2026
Prednisolone acetate ophthalmic suspension (1%)Phase 2 · Non-infectious Anterior UveitisClinicalTrials.gov · fetched Nov 12, 2026
Reproxalap Ophthalmic Solution (0.1%)Phase 2 · Dry Eye SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BIDPhase 2 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
Reproxalap Ophthalmic Solution (0.25%)Phase 2 · Dry Eye SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Vehicle Ophthalmic SolutionPhase 2 · Dry Eye SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BIDPhase 2 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

A Clinical Trial Evaluating Patients With Primary Vitreoretinal LymphomaPHASE3 · RECRUITING · started Feb 1, 2026ClinicalTrials.gov NCT07402876 · fetched Nov 12, 2026
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)PHASE2 · COMPLETED · started Nov 4, 2024ClinicalTrials.gov NCT06685692 · fetched Nov 12, 2026
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseasePHASE3 · COMPLETED · started Jun 24, 2024ClinicalTrials.gov NCT06493604 · fetched Nov 12, 2026
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseasePHASE3 · COMPLETED · started Apr 29, 2024ClinicalTrials.gov NCT06424444 · fetched Nov 12, 2026
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)PHASE2 · COMPLETED · started Feb 15, 2023ClinicalTrials.gov NCT05717920 · fetched Nov 12, 2026
Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic SyndromePHASE2 · WITHDRAWN · started Jan 1, 2023ClinicalTrials.gov NCT05599815 · fetched Nov 12, 2026
A Study in Subjects With Retinitis PigmentosaPHASE2 · COMPLETED · started Jul 14, 2022ClinicalTrials.gov NCT05392179 · fetched Nov 12, 2026
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic CoughPHASE2 · COMPLETED · started Apr 7, 2022ClinicalTrials.gov NCT05392192 · fetched Nov 12, 2026
A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol LevelsPHASE1_PHASE2 · COMPLETED · started Nov 15, 2021ClinicalTrials.gov NCT05487404 · fetched Nov 12, 2026
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseasePHASE3 · COMPLETED · started Aug 28, 2021ClinicalTrials.gov NCT05062330 · fetched Nov 12, 2026
A Clinical Trial to Assess Subjects With Dry Eye Disease.PHASE2 · COMPLETED · started Jun 15, 2021ClinicalTrials.gov NCT04971031 · fetched Nov 12, 2026
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque PsoriasisPHASE2 · COMPLETED · started May 7, 2021ClinicalTrials.gov NCT04908514 · fetched Nov 12, 2026
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.PHASE2 · COMPLETED · started Mar 31, 2021ClinicalTrials.gov NCT04847544 · fetched Nov 12, 2026
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseasePHASE3 · COMPLETED · started Jan 26, 2021ClinicalTrials.gov NCT04735393 · fetched Nov 12, 2026
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseasePHASE2_PHASE3 · COMPLETED · started Nov 21, 2020ClinicalTrials.gov NCT04674358 · fetched Nov 12, 2026
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative VitreoretinopathyPHASE3 · COMPLETED · started Nov 15, 2019ClinicalTrials.gov NCT04136366 · fetched Nov 12, 2026
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye DiseasePHASE2 · COMPLETED · started Apr 23, 2019ClinicalTrials.gov NCT03916042 · fetched Nov 12, 2026
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseasePHASE3 · COMPLETED · started Apr 16, 2019ClinicalTrials.gov NCT03879863 · fetched Nov 12, 2026
A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic ConjunctivitisPHASE1_PHASE2 · COMPLETED · started Sep 8, 2018ClinicalTrials.gov NCT03660878 · fetched Nov 12, 2026
RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)PHASE3 · COMPLETED · started Jul 18, 2018ClinicalTrials.gov NCT03445650 · fetched Nov 12, 2026
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic ConjunctivitisPHASE3 · COMPLETED · started Mar 30, 2018ClinicalTrials.gov NCT03494504 · fetched Nov 12, 2026
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseasePHASE2 · COMPLETED · started Jan 2, 2018ClinicalTrials.gov NCT03404115 · fetched Nov 12, 2026
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye SyndromePHASE2 · COMPLETED · started May 15, 2017ClinicalTrials.gov NCT03162783 · fetched Nov 12, 2026
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.PHASE3 · COMPLETED · started Apr 26, 2017ClinicalTrials.gov NCT03131154 · fetched Nov 12, 2026
A Safety and Efficacy Study of NS2 in Patients With Anterior UveitisPHASE2 · COMPLETED · started Mar 1, 2015ClinicalTrials.gov NCT02406209 · fetched Nov 12, 2026

SEC filings12

8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Sep 29, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 15, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 10, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 1, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 20, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 1, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Mar 17, 2026 · fetched Nov 12, 2026